Switch theme
Sign up to access all valuation multiples
Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.
1941
1.2K+
LTM Revenue $240M
Last FY EBITDA $22.8M
$201M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kewaunee Scientific has a last 12-month revenue (LTM) of $240M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Kewaunee Scientific achieved revenue of $240M and an EBITDA of $22.8M.
Kewaunee Scientific expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kewaunee Scientific valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $240M | XXX | $240M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $68.9M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 29% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $22.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 9% | XXX | XXX | XXX |
| EBIT | n/a | XXX | $17.8M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $11.4M | XXX | $11.4M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $22.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Kewaunee Scientific's stock price is $56.
Kewaunee Scientific has current market cap of $165M, and EV of $201M.
See Kewaunee Scientific trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $201M | $165M | XXX | XXX | XXX | XXX | $5.37 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Kewaunee Scientific has market cap of $165M and EV of $201M.
Kewaunee Scientific's trades at 0.9x EV/Revenue multiple, and 9.5x EV/EBITDA.
Equity research analysts estimate Kewaunee Scientific's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kewaunee Scientific has a P/E ratio of 14.5x.
See valuation multiples for Kewaunee Scientific and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $165M | XXX | $165M | XXX | XXX | XXX |
| EV (current) | $201M | XXX | $201M | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 9.5x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 11.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 14.5x | XXX | 11.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 14.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKewaunee Scientific's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $41K for the same period.
Kewaunee Scientific's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kewaunee Scientific's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kewaunee Scientific and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $41K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kewaunee Scientific acquired XXX companies to date.
Last acquisition by Kewaunee Scientific was XXXXXXXX, XXXXX XXXXX XXXXXX . Kewaunee Scientific acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kewaunee Scientific founded? | Kewaunee Scientific was founded in 1941. |
| Where is Kewaunee Scientific headquartered? | Kewaunee Scientific is headquartered in United States of America. |
| How many employees does Kewaunee Scientific have? | As of today, Kewaunee Scientific has 1.2K+ employees. |
| Who is the CEO of Kewaunee Scientific? | Kewaunee Scientific's CEO is Mr. Thomas D. Hull, III. |
| Is Kewaunee Scientific publicy listed? | Yes, Kewaunee Scientific is a public company listed on NAS. |
| What is the stock symbol of Kewaunee Scientific? | Kewaunee Scientific trades under KEQU ticker. |
| When did Kewaunee Scientific go public? | Kewaunee Scientific went public in 1972. |
| Who are competitors of Kewaunee Scientific? | Similar companies to Kewaunee Scientific include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Kewaunee Scientific? | Kewaunee Scientific's current market cap is $165M |
| What is the current revenue of Kewaunee Scientific? | Kewaunee Scientific's last 12 months revenue is $240M. |
| What is the current EV/Revenue multiple of Kewaunee Scientific? | Current revenue multiple of Kewaunee Scientific is 0.8x. |
| Is Kewaunee Scientific profitable? | Yes, Kewaunee Scientific is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
